ECE 2021
Hypoparathyreodismus neu bewertet
www.endowissen.tv | Beiträge | ECE 2021
ECE 2021
Hypoparathyreodismus neu bewertet
ECE 2021
Neue Entwicklungen bei AGS-Therapie
ECE 2021
Cushing-Syndrom - aktuelle Therapielandschaft
ECE 2021
Endokrine Disruptoren
ECE 2021
Sequenztherapie der Osteoporose
ECE 2021
Cardiovascular events in adult patients with chronic…
ECE 2021
The effect of intra-operative autofluorescence…
ECE 2021
Bisphosphonates after Denosumab withdrawal reduce the…
ECE 2021
News about hypophosphatasia
ECE 2021
Quantifying the real-world clinical and economic burden…
ECE 2021
Safety, tolerability and pharmacodynamics of AZP-3601,…
ECE 2021
Challenges of hypoparathyroidism
ECE 2021
Deficiency or insufficiency of vitamin D and the…
ECE 2021
AAV liver gene therapy-mediated inhibition of FGF23…
ECE 2021
Bone consequences of high dose denosumab to treat an…
ECE 2021
Non-nuclear cataracts in hypoparathyroidism are…
ECE 2021
TransCon PTH as a potential hormone replacement therapy…
ECE 2021
One year in bone
ECE 2021
Risk of chronic kidney disease and change in GFR in…
ECE 2021
Adverse events of mitotane treatment in patients with…
ECE 2021
Fascin-1, a novel-circulating marker for the prognosis…
ECE 2021
Tildacerfont for the treatment of patients with classic…
ECE 2021
Novel treatment and monitoring options for CAH
ECE 2021
Neuroendocrine stress response at single cell…
ECE 2021
Primary results from MATCH: A randomised controlled…
ECE 2021
Pre-operative hypercortisolism and post-operative…
ECE 2021
Steroid metabolomics for the detection of malignancy in…
ECE 2021
Salivary steroid and 11‑oxygenated androgen profiles in…
ECE 2021
Results of the ADIUVO trial, the first randomized study…
ECE 2021
Thymic neuroendocrine tumor and mortality in MEN 1…
ECE 2021
Reassessment of the diagnostic criteria of insulinoma:…
ECE 2021
Osilodrostat provides sustained control of urinary free…
ECE 2021
Identification of a dose range for once daily oral…
ECE 2021
GH replacement in adults
ECE 2021
Osilodrostat, a potent oral 11β-hydroxylase inhibitor
ECE 2021
A Phase 3 Large International Noninferiority Trial…
ECE 2021
Can the follow-up imaging interval for non-functioning…
ECE 2021
Metyrapone treatment in endogenous Cushing’s syndrome.…
ECE 2021
Addition of cabergoline to oral octreotide capsules may…
ECE 2021
Non-contraceptive therapeutic use of combined oral…
ECE 2021
Effect of IL-1 receptor antagonism on hyperandrogenemia…
ECE 2021
Long-term effects of testosterone replacement therapy
ECE 2021
Monogenic variants in the Finnish Pediatric Diabetes…
ECE 2021
Endocrine Disruptors - a key challenge for…
ECE 2021
COVID-19 and hormones – the role of Endocrinologists in…
Für den erfolgreichen Abschluss der Fortbildungsmodule ist die korrekte (mind. 70%) Beantwortung der Lernerfolgskontrolle für das jeweilige Modul verpflichtend.
Jetzt gleich den Fragebogen ausfüllen!